PA
PHAT icon

Parallel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Parallel Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08K Hold
100
– – ﹤0.01% 3672
2026
Q1 		$1.11K Hold
100
– – ﹤0.01% 3521
2025
Q4 		$1.66K Sell
100
-86
-46% -$1.23K ﹤0.01% 3180
2025
Q3 		$2.19K Hold
186
– – ﹤0.01% 3022
2025
Q2 		$1.78K Sell
186
-143
-43% -$791 ﹤0.01% 3066
2025
Q1 		$2.06K Buy
+329
New +$2K ﹤0.01% 2969
2023
Q1 		– Sell
-29
Closed -$325 – 3482
2022
Q4 		$325 Hold
29
– – ﹤0.01% 3115
2022
Q3 		$0 Buy
+29
New +$276 ﹤0.01% 3408
2022
Q2 		– Sell
-80
Closed -$1K – 3265
2022
Q1 		$1K Buy
80
+8
+11% +$129 ﹤0.01% 2808
2021
Q4 		$1K Buy
+72
New +$1.69K ﹤0.01% 2932

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Parallel Advisors's PHAT Position: Q2 2026 in Review

Parallel Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 100 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3672.

Parallel Advisors first reported a position in PHAT in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.19K in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Parallel Advisors held 100 shares of Phathom Pharmaceuticals worth $1.08K as of Q2 2026.
  • Parallel Advisors left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3672 holding.
  • Parallel Advisors first reported a position in Phathom Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
  • Parallel Advisors's Phathom Pharmaceuticals position peaked at $2.19K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.